Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
OraSure Technologies, Inc is a medical instruments & supplies business based in the US. OraSure Technologies shares (OSUR) are listed on the NASDAQ and all prices are listed in US Dollars. OraSure Technologies employs 472 staff and has a trailing 12-month revenue of around USD$159.7 million.
|Latest market close||USD$12.65|
|52-week range||USD$5.23 - USD$19.75|
|50-day moving average||USD$13.7715|
|200-day moving average||USD$13.3367|
|Wall St. target price||USD$19.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.2|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-10)||N/A|
|1 month (2020-12-21)||8.03%|
|3 months (2020-10-17)||N/A|
|6 months (2020-07-17)||N/A|
|1 year (2020-01-17)||N/A|
|2 years (2019-01-17)||N/A|
|3 years (2018-01-17)||N/A|
|5 years (2016-01-17)||N/A|
Valuing OraSure Technologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of OraSure Technologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
OraSure Technologies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, OraSure Technologies shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
OraSure Technologies's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into OraSure Technologies's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
OraSure Technologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.4 million.
The EBITDA is a measure of a OraSure Technologies's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$159.7 million|
|Gross profit TTM||USD$94.3 million|
|Return on assets TTM||-0.88%|
|Return on equity TTM||-4.16%|
|Market capitalisation||USD$859.7 million|
TTM: trailing 12 months
There are currently 7.1 million OraSure Technologies shares held short by investors – that's known as OraSure Technologies's "short interest". This figure is 1.2% up from 7.0 million last month.
There are a few different ways that this level of interest in shorting OraSure Technologies shares can be evaluated.
OraSure Technologies's "short interest ratio" (SIR) is the quantity of OraSure Technologies shares currently shorted divided by the average quantity of OraSure Technologies shares traded daily (recently around 2.1 million). OraSure Technologies's SIR currently stands at 3.34. In other words for every 100,000 OraSure Technologies shares traded daily on the market, roughly 3340 shares are currently held short.
However OraSure Technologies's short interest can also be evaluated against the total number of OraSure Technologies shares, or, against the total number of tradable OraSure Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OraSure Technologies's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 OraSure Technologies shares in existence, roughly 100 shares are currently held short) or 0.1128% of the tradable shares (for every 100,000 tradable OraSure Technologies shares, roughly 113 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against OraSure Technologies.
Find out more about how you can short OraSure Technologies stock.
We're not expecting OraSure Technologies to pay a dividend over the next 12 months.
OraSure Technologies's shares were split on a 3:1 basis on 8 April 1987. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your OraSure Technologies shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for OraSure Technologies shares which in turn could have impacted OraSure Technologies's share price.
Over the last 12 months, OraSure Technologies's shares have ranged in value from as little as $5.23 up to $19.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OraSure Technologies's is 0.2937. This would suggest that OraSure Technologies's shares are less volatile than average (for this exchange).
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, and OraSure QuickFlu Rapid Flu A&B test; OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; tuberculosis products; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.